Calypso Biotech

Calypso Enters into Agreement to Be Acquired by Novartis

Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications 8 January 2024 -- Amsterdam, the Netherlands -- Calypso Biotech, a leader...
Gustav Mahlerplein 102 1082 MA Amsterdam The Netherlands

+41 22 552 3307